The activity of cefmenoxime (SCE-1365), 7,8-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]ceph-3-em-4-carboxylic acid, was compared with that of other cephalosporins. Cefinenoxime exhibited high activity against a wide variety of gram-positive and gramnegative bacteria. The in vitro activity of cefmenoxime against Streptococcus pyogenes, Haemophilus influenzae, and Enterobacteriaceae, including indolepositive Proteus, Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii, was 10 to 1,000 times greater than that of several other cephalosporins. Against Pseudomonas aeruginosa, cefmenoxime showed activity two to four times that of sulbenicillin and carbenicillin but less than that of cefsulodin. Variation in pH, addition of horse serum, and type of growth medium had definite effects on the activity of cefmenoxime, and the inoculum size affected the activity against bacterial species. In Escherichia coli cefmenoxime showed marked affinity for penicillin-binding protein 3 (PBP-3), followed by PBP-1 (1A and 1B). This affinity profile was well correlated with its filamentous cell-forming activity under extremely low drug concentrations and with its bactericidal activity against microorganisms. The high in vitro activity of cefmenoxime was reflected in the degree of protection observed in mice infected intraperitoneally with a wide variety of gram-positive and gram-negative bacteria. Furthermore, cefmenoxime showed good therapeutic activity against infection models in mice such as respiratory tract infection caused by Klebsiellapneumoniae and urinary tract infection caused by Proteus mirabilis.In recent years, with the increasing use of cephalosporins, an increasing number of infections caused by cephalosporin-resistant bacteria have been observed. The present report concerns the activity of cefmenoxime (SCE-1365),

Two N-tert-butoxy-2,6-diaryl-4-(4-pyridyl)phenylaminyls (1) and three N-tert-butoxy-2,6-diaryl-4-(1H-imidazol-1-yl)phenylaminyls (2) were prepared by the reaction of the lithium salts of the corresponding anilines with tert-butyl peroxybenzoate. Although 1 could not be isolated as radical crystals, 2 was successfully obtained as red crystals. The X-ray crystallographic analysis and magnetic susceptibility measurements were performed for one isolated radical.

SUMMARYEffects of various inhibitors on the intracellular accumulation of glycerol and inorganic ions in a salt-tolerant yeast, Zygosaccharomyces rouxii, were examined for several hours during NaCl-induced salt stress. Cycloheximide strongly inhibited the intracellular accumulation of glycerol during salt stress but chloramphenicol did not. Rapid activation of plasma-membrane ATPase was apparent within 5 min after the start of salt stress and after 1 h a second, slower activation occurred. ATP was maintained at a higher level during salt stress than that in its absence. Experiments with various other inhibitors demonstrated a close relationship between synthesis of glycerol, activation of plasma membrane ATPase and increases in levels of ATP. These results suggestCorrespondence to: T. Yagi,

The in vitro antibacterial activity of DU-6681a, a parent compound of DZ-2640, against gram-positive and -negative bacteria was compared with those of penems and cephalosporins currently available. MICs at which 90% of the isolates are inhibited (MIC90s) of the compound for clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-susceptible and -resistant strains, were 0.10, 25, and 12.5 microg/ml, respectively. DU-6681a inhibited the growth of all strains of Streptococcus pyogenes and of penicillin-susceptible and -insusceptible Streptococcus pneumoniae at 0.006, 0.025, and 0.20 microg/ml, respectively, and MIC90s of the compound were 6.25 and >100 microg/ml for Enterococcus faecalis and Enterococcus faecium, respectively. MIC90s of DU-6681a were 0.20, 0.10, and 0.025 microg/ml for Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae, respectively. For Pseudomonas aeruginosa, the MIC50 and MIC90 of DU-6681a were 25 and 50 microg/ml, respectively. DU-6681a activity was not affected by different media, varied inoculum size (10(4) to 10(7) CFU), or the addition of human serum but was decreased under acidic conditions against gram-negative bacteria, under alkaline conditions against gram-positive bacteria, and in human urine, as was the activity of the other antibiotics tested. The frequency of spontaneous resistance to DU-6681a was less than or equal to those of the reference compounds. Time-kill curve studies demonstrated the bactericidal action of DU-6681a against S. aureus, S. pneumoniae, Escherichia coli, and H. influenzae.

A respiration-deficient (RD) mutant was isolated from the petite-negative, salt-tolerant yeast Zygosaccharomyces rouxii. One strain among sixteen glycerol-non-utilizing mutants exhibited vigorous liberation of CO2 but no uptake of O2. Furthermore, this strain lacked cytochrome aa3 and had a reduced level of cytochrome b. The few mitochondria found in cells of this strain contained few or no cristae. Salt tolerance and intracellular accumulation of glycerol by the RD strain were almost equal to that of the wild-type strain in media containing NaCl up to 2.5 M. In media with more than 3 M NaCl, the growth of the RD mutant was retarded and the intracellular accumulation of glycerol was depressed in spite of ample production.